Upcoming presentation

Q2 2017 presentation and Capital Markets Day invitation

Biotec Pharmacon ASA (OSE:Biotec) will host a Capital Markets Day (CMD) with strategic update and outlook on Thursday, 17 August 2017 following the Q2 presentation.

The presentation will among other include:

  • Woulgan – driving sales in key markets and next generation products
  • Animal Health – continue securing high volume sales
  • Human Health – competitive priced high quality prdoduct
  • Enzymes – taking ArcticZymes to the next level
  • Cancer – opportunity with untapped potential
  • Execution on corporate strategy

For practical reasons, investors, analysts and journalists coming to the event are encouraged to register via email to ir@biotec.no by 11th August 2017.

The Q2 and the CMD presentations will be webcasted live and made available on biotec.no and through NewsWeb on 17 August 2017. It will be possible to post questions through the webcast console.

View the webcast

  • Recent news

  • Extended distribution agreement with Rogg Verbandstoffe in Germany

    (Tromsø, 18 July 2017) Biotec Pharmacon's (”Biotec”, OSE: BIOTEC) subsidiary Biotec Betaglucans AS has extended the distribution agreement for Woulgan in Germany with Rogg Verbandstoffe (Rogg) for an additional 12 months with automatic renewal thereafter Svein Lien, CEO of Biotec Pharmacon ASA says: -We are very pleased to extend this agreement, providing…

    Continue reading

Latest presentation

Presentation of the first quarter 2017

Loading video...

Biotec Pharmacon ASA (”Biotec”, OSE: BIOTEC) reported sales of NOK 18.2 million (17.3) in the first quarter of 2017, and a negative EBITDA of NOK 4.1 million (-3.5). Woulgan® generated sales of NOK 0.4 million during the first quarter primarily to Germany. ArcticZymes continued its positive sales growth from the previous quarters.…

View more